OmniaBio

At the heart of what we do is a culture of innovation at OmniaBio, where our commitment to advancing cell and gene therapy manufacturing drives us to deliver life-saving solutions to patients worldwide. Founded as a subsidiary of the Centre for Commercialization of Regenerative Medicine (CCRM) in July 2022, we are dedicated to revolutionizing the therapeutic landscape with our cutting-edge approach to contract development and manufacturing (CDMO).

Our expertise spans a decade of collective experience in developing both autologous and allogeneic cell therapies. We collaborate closely with our clients, providing personalized services that ensure a seamless transition from early-stage development to large-scale commercial manufacturing. This unique partnership empowers us to navigate the complexities of process development and good manufacturing practices (GMP) efficiently. By integrating advanced technologies, including AI models and robotics, we enhance affordability and accessibility, aligning our goals with those of our clients and the patients they serve.